The Institute for Clinical and Economics Review (ICER) announced Monday, May 20, that it is developing two new tools aimed at streamlining stakeholders' ability to examine the organization's "entire body of work" to bolster decision-making. ICER made the announcement during the International […]
ICER Says J&J’s Spravato is Overpriced
Johnson & Johnson's new therapy to treat resistant depression, Spravato, is overpriced, according to the Institute for Clinical and Economic Review (ICER), though it could provide a "comparable, small, or substantial net health benefit" for patients. According to a FiercePharma report, the […]
ICER, IPD Announce New Analytics Partnership
The Institute for Clinical and Economic Review (ICER) will leverage IPD Analytics' (IPD) data and insights to bolster its reviews of "high-impact, high-cost therapies" as part of a new collaborative effort, the organizations announced last week. The initiative was announced Thursday, May 9. IPD […]
Novartis’ Zolgensma About to Hit Market with Record Price Tag
Novartis' new gene therapy for the treatment of spinal muscular atrophy (SMA) is soon to hit the market with an expected price of roughly $2 million, the Wall Street Journal reports. While the drugmaker has not yet set the price of Zolgensma, according to the report, executives say the health […]
ICER: Price of Esketamine for Treatment-Resistant Depression Exceeds Cost-Effectiveness Thresholds
The price of Janssen's esketamine for the treatment of treatment-resistant depression (TRD) exceeds commonly-cited $50,000-$150,000 quality-adjusted life year (QALY) cost thresholds, the Institute for Clinical and Economic Review (ICER) suggests in a recent evidence report. ICER found esketamine […]
ICER Seeks Public Input for 2020 Framework
The Institute for Clinical and Economics Review (ICER) last week opened a public comment period to generate feedback on its upcoming 2020 value assessment framework. According to a press release, ICER will accept comments through Monday, June 10, and will publish draft revisions to its current […]
ICER: Price of Novartis’ Siponimod Exceeds Common QALY, LYG Thresholds
The Institute for Clinical and Economic Review (ICER) on Thursday, May 2, suggested in a recently-released evidence report that Novartis' siponimod, which is used in the treatment of secondary progressive multiple sclerosis (SPMS), "far exceeds" common quality-adjusted life year and life year gained […]
Recent ICON Paper Points to Higher-Than Expected Impact of ICER Assessments
A recent paper by ICON suggests the Institute for Clinical and Economic Review's (ICER) drug assessments carry more weight in decision-making among payers than originally expected, according to an article published on Forbes. The white paper, titled "Industry Perceptions and Expectations: The Role […]
ICER Posts Draft Scoping Document for RA Treatments
The Institute for Clinical and Economic Review (ICER) on Thursday, April 11, released a draft scoping document for a planned review of treatments for rheumatoid arthritis (RA). According to a press release, ICER's assessment will include new data on RA treatments since its 2017 review. "In […]
ICER Plans Assessment of Type 2 Diabetes Treatments
The Institute for Clinical and Economic Review (ICER) announced Thursday, April 11, that it will review the comparative clinical effectiveness and value of several treatments for type 2 diabetes. According to a press release, ICER will assess Novo Nordisk's oral semaglutide and compare it to Novo […]
